title: Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma.
abstract: Twice-weekly bortezomib has proven activity in mantle cell (MCL) and indolent lymphomas. This study explored a weekly schedule of bortezomib in follicular lymphoma (FL) and MCL. Although weekly bortezomib was better tolerated, the overall response rate (ORR) was inferior (18% vs. 50%, P = 0.02) with no complete remissions (CR) (compared with 18% CR for the twice-weekly schedule). Progression-free survival (PFS) was not different. The weekly schedule of bortezomib was less toxic, but yielded fewer and lower quality responses than twice-weekly bortezomib. Given the similar PFS, the weekly schedule may still be appropriate for some patients.
authors.affiliation: Department of Medicine, Memorial Sloan Kettering Cancer Center, Columbia University, New York, NY 10021, USA. gerecitj@mskcc.org
authors.forename: John
authors.initials: J
authors.lastname: Gerecitano
authors.forename: Carol
authors.initials: C
authors.lastname: Portlock
authors.forename: Craig
authors.initials: C
authors.lastname: Moskowitz
authors.forename: Paul
authors.initials: P
authors.lastname: Hamlin
authors.forename: David
authors.initials: D
authors.lastname: Straus
authors.forename: Andrew D
authors.initials: AD
authors.lastname: Zelenetz
authors.forename: Zhigang
authors.initials: Z
authors.lastname: Zhang
authors.forename: Otilia
authors.initials: O
authors.lastname: Dumitrescu
authors.forename: Debra
authors.initials: D
authors.lastname: Sarasohn
authors.forename: Dorothy
authors.initials: D
authors.lastname: Lin
authors.forename: Jennifer
authors.initials: J
authors.lastname: Pappanicholaou
authors.forename: Barbara M
authors.initials: BM
authors.lastname: Cortelli
authors.forename: Ellen
authors.initials: E
authors.lastname: Neylon
authors.forename: Rachel
authors.initials: R
authors.lastname: Hamelers
authors.forename: John
authors.initials: J
authors.lastname: Wright
authors.forename: Owen A
authors.initials: OA
authors.lastname: O'Connor
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001897:Boronic Acids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000069286:Bortezomib; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008224:Lymphoma, Follicular / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011480:Protease Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011719:Pyrazines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D011480:Protease Inhibitors; D011719:Pyrazines; D000069286:Bortezomib